Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Down 3.9 %

NERV stock opened at $1.97 on Friday. The business has a 50-day simple moving average of $2.23 and a 200 day simple moving average of $2.46. Minerva Neurosciences has a 52 week low of $1.90 and a 52 week high of $9.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Minerva Neurosciences stock. Northern Trust Corp raised its holdings in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,878 shares of the biopharmaceutical company’s stock after acquiring an additional 13,829 shares during the period. Northern Trust Corp owned about 0.53% of Minerva Neurosciences worth $82,000 at the end of the most recent quarter. 34.56% of the stock is owned by hedge funds and other institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.